Current Challenges Towards the Development of a Blood Test for Parkinson’s Disease
Parkinson’ disease (PD) is the second most prevalent neurodegenerative disease worldwide. To date, there is no disease-modifying agent, and current medical treatment only provides symptomatic benefits. Early diagnosis of PD would be useful in clinical practice to identify patients for clinical trial...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2014-10-01
|
Series: | Diagnostics |
Subjects: | |
Online Access: | http://www.mdpi.com/2075-4418/4/4/153 |
id |
doaj-642495ce082040cb9049d59edfd9ce8b |
---|---|
record_format |
Article |
spelling |
doaj-642495ce082040cb9049d59edfd9ce8b2020-11-24T21:29:16ZengMDPI AGDiagnostics2075-44182014-10-014415316410.3390/diagnostics4040153diagnostics4040153Current Challenges Towards the Development of a Blood Test for Parkinson’s DiseaseJose A. Santiago0Judith A. Potashkin1The Cellular and Molecular Pharmacology Department, The Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064-3037, USAThe Cellular and Molecular Pharmacology Department, The Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064-3037, USAParkinson’ disease (PD) is the second most prevalent neurodegenerative disease worldwide. To date, there is no disease-modifying agent, and current medical treatment only provides symptomatic benefits. Early diagnosis of PD would be useful in clinical practice to identify patients for clinical trials, test potential drugs and neuroprotective agents and track their therapeutic effect. Considerable progress has been made in the discovery and validation of diagnostic biomarkers for PD. In particular, blood-based biomarkers have shown promise in identifying PD patients in samples from independent clinical trials. Evaluation of these biomarkers in de novo patients and individuals at risk for PD remains a top priority. Here, we review the current advances and challenges toward the clinical translation of these biomarkers into a blood-based test for PD.http://www.mdpi.com/2075-4418/4/4/153biomarkersbloodParkinson’s disease |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jose A. Santiago Judith A. Potashkin |
spellingShingle |
Jose A. Santiago Judith A. Potashkin Current Challenges Towards the Development of a Blood Test for Parkinson’s Disease Diagnostics biomarkers blood Parkinson’s disease |
author_facet |
Jose A. Santiago Judith A. Potashkin |
author_sort |
Jose A. Santiago |
title |
Current Challenges Towards the Development of a Blood Test for Parkinson’s Disease |
title_short |
Current Challenges Towards the Development of a Blood Test for Parkinson’s Disease |
title_full |
Current Challenges Towards the Development of a Blood Test for Parkinson’s Disease |
title_fullStr |
Current Challenges Towards the Development of a Blood Test for Parkinson’s Disease |
title_full_unstemmed |
Current Challenges Towards the Development of a Blood Test for Parkinson’s Disease |
title_sort |
current challenges towards the development of a blood test for parkinson’s disease |
publisher |
MDPI AG |
series |
Diagnostics |
issn |
2075-4418 |
publishDate |
2014-10-01 |
description |
Parkinson’ disease (PD) is the second most prevalent neurodegenerative disease worldwide. To date, there is no disease-modifying agent, and current medical treatment only provides symptomatic benefits. Early diagnosis of PD would be useful in clinical practice to identify patients for clinical trials, test potential drugs and neuroprotective agents and track their therapeutic effect. Considerable progress has been made in the discovery and validation of diagnostic biomarkers for PD. In particular, blood-based biomarkers have shown promise in identifying PD patients in samples from independent clinical trials. Evaluation of these biomarkers in de novo patients and individuals at risk for PD remains a top priority. Here, we review the current advances and challenges toward the clinical translation of these biomarkers into a blood-based test for PD. |
topic |
biomarkers blood Parkinson’s disease |
url |
http://www.mdpi.com/2075-4418/4/4/153 |
work_keys_str_mv |
AT joseasantiago currentchallengestowardsthedevelopmentofabloodtestforparkinsonsdisease AT judithapotashkin currentchallengestowardsthedevelopmentofabloodtestforparkinsonsdisease |
_version_ |
1725966509865435136 |